| . | Patients . |
|---|---|
| Standardized endpoints (VARC-2) | |
| Device success | |
| All patients | 42/43 (98%) |
| Patients with cardiogenic shock | 22/23 (98%) |
| Patients with impaired LV or RV function, pulmonary hypertension with enlarged RV | 20/20 (100%) |
| Safety <30 days | |
| All patients | 34/43 (79%) |
| Patients with cardiogenic shock | 15/23 (65%) |
| Patients with impaired LV or RV function, pulmonary hypertension with enlarged RV | 19/20 (95%) |
| Time of hospitalization (days) | |
| Length of stay in intensive care unit | 3.2 (0.3–66) |
| Total length of stay | 11.8 (2.7–103) |
| Thirty-day mortality | |
| All patients | 6 (14%) |
| Patients with cardiogenic shock | 6 (28.6%) |
| Patients with impaired LV or RV function, pulmonary hypertension with enlarged RV | No death |
| Survival | |
| Six-month survival | 60 ± 8% |
| Patients with cardiogenic shock | 41 ± 11% |
| Patients with impaired LV or RV function, or pulmonary hypertension with enlarged RV | 86 ± 9.5% |
| One-year survival | 57 ± 8.4% |
| Patients with cardiogenic shock | 36 ± 11% |
| Patients with impaired LV or RV function, or pulmonary hypertension with enlarged RV | 86 ± 9.5% |
| Two-year survival | 49 ± 10% |
| Patients with cardiogenic shock | 36 ± 11% |
| Patients with impaired LV or RV function, or pulmonary hypertension with enlarged RV | 68 ± 17% |
| . | Patients . |
|---|---|
| Standardized endpoints (VARC-2) | |
| Device success | |
| All patients | 42/43 (98%) |
| Patients with cardiogenic shock | 22/23 (98%) |
| Patients with impaired LV or RV function, pulmonary hypertension with enlarged RV | 20/20 (100%) |
| Safety <30 days | |
| All patients | 34/43 (79%) |
| Patients with cardiogenic shock | 15/23 (65%) |
| Patients with impaired LV or RV function, pulmonary hypertension with enlarged RV | 19/20 (95%) |
| Time of hospitalization (days) | |
| Length of stay in intensive care unit | 3.2 (0.3–66) |
| Total length of stay | 11.8 (2.7–103) |
| Thirty-day mortality | |
| All patients | 6 (14%) |
| Patients with cardiogenic shock | 6 (28.6%) |
| Patients with impaired LV or RV function, pulmonary hypertension with enlarged RV | No death |
| Survival | |
| Six-month survival | 60 ± 8% |
| Patients with cardiogenic shock | 41 ± 11% |
| Patients with impaired LV or RV function, or pulmonary hypertension with enlarged RV | 86 ± 9.5% |
| One-year survival | 57 ± 8.4% |
| Patients with cardiogenic shock | 36 ± 11% |
| Patients with impaired LV or RV function, or pulmonary hypertension with enlarged RV | 86 ± 9.5% |
| Two-year survival | 49 ± 10% |
| Patients with cardiogenic shock | 36 ± 11% |
| Patients with impaired LV or RV function, or pulmonary hypertension with enlarged RV | 68 ± 17% |
Data are presented as n/n, %, or estimate, standard error.
LV: left ventricular; RV: right ventricular.
| . | Patients . |
|---|---|
| Standardized endpoints (VARC-2) | |
| Device success | |
| All patients | 42/43 (98%) |
| Patients with cardiogenic shock | 22/23 (98%) |
| Patients with impaired LV or RV function, pulmonary hypertension with enlarged RV | 20/20 (100%) |
| Safety <30 days | |
| All patients | 34/43 (79%) |
| Patients with cardiogenic shock | 15/23 (65%) |
| Patients with impaired LV or RV function, pulmonary hypertension with enlarged RV | 19/20 (95%) |
| Time of hospitalization (days) | |
| Length of stay in intensive care unit | 3.2 (0.3–66) |
| Total length of stay | 11.8 (2.7–103) |
| Thirty-day mortality | |
| All patients | 6 (14%) |
| Patients with cardiogenic shock | 6 (28.6%) |
| Patients with impaired LV or RV function, pulmonary hypertension with enlarged RV | No death |
| Survival | |
| Six-month survival | 60 ± 8% |
| Patients with cardiogenic shock | 41 ± 11% |
| Patients with impaired LV or RV function, or pulmonary hypertension with enlarged RV | 86 ± 9.5% |
| One-year survival | 57 ± 8.4% |
| Patients with cardiogenic shock | 36 ± 11% |
| Patients with impaired LV or RV function, or pulmonary hypertension with enlarged RV | 86 ± 9.5% |
| Two-year survival | 49 ± 10% |
| Patients with cardiogenic shock | 36 ± 11% |
| Patients with impaired LV or RV function, or pulmonary hypertension with enlarged RV | 68 ± 17% |
| . | Patients . |
|---|---|
| Standardized endpoints (VARC-2) | |
| Device success | |
| All patients | 42/43 (98%) |
| Patients with cardiogenic shock | 22/23 (98%) |
| Patients with impaired LV or RV function, pulmonary hypertension with enlarged RV | 20/20 (100%) |
| Safety <30 days | |
| All patients | 34/43 (79%) |
| Patients with cardiogenic shock | 15/23 (65%) |
| Patients with impaired LV or RV function, pulmonary hypertension with enlarged RV | 19/20 (95%) |
| Time of hospitalization (days) | |
| Length of stay in intensive care unit | 3.2 (0.3–66) |
| Total length of stay | 11.8 (2.7–103) |
| Thirty-day mortality | |
| All patients | 6 (14%) |
| Patients with cardiogenic shock | 6 (28.6%) |
| Patients with impaired LV or RV function, pulmonary hypertension with enlarged RV | No death |
| Survival | |
| Six-month survival | 60 ± 8% |
| Patients with cardiogenic shock | 41 ± 11% |
| Patients with impaired LV or RV function, or pulmonary hypertension with enlarged RV | 86 ± 9.5% |
| One-year survival | 57 ± 8.4% |
| Patients with cardiogenic shock | 36 ± 11% |
| Patients with impaired LV or RV function, or pulmonary hypertension with enlarged RV | 86 ± 9.5% |
| Two-year survival | 49 ± 10% |
| Patients with cardiogenic shock | 36 ± 11% |
| Patients with impaired LV or RV function, or pulmonary hypertension with enlarged RV | 68 ± 17% |
Data are presented as n/n, %, or estimate, standard error.
LV: left ventricular; RV: right ventricular.
This PDF is available to Subscribers Only
View Article Abstract & Purchase OptionsFor full access to this pdf, sign in to an existing account, or purchase an annual subscription.
